Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Pancreatin and Improved Nonalcoholic Fatty Liver Disease

Doses used in studies

g/day: 3 (median 3, IQR 3–3) — 1 study

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

Safety in these studies

adverse eventsNo significant difference
There were no adverse effects.
from: Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic
Overall tolerabilityReported
There were no adverse effects.
from: Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic

1 of 1 paper

Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial.
- 2020-12
- RCT
- Journal of the American College of Surgeons 231(6)
- - Koya Yasukawa
  - Akira Shimizu
  - Takahide Yokoyama
  - Koji Kubota
  - Tsuyoshi Notake
  - Hitoshi Seki
  - Akira Kobayashi
  - Yuji Soejima
- PubMed: 32927075
- DOI: 10.1016/j.jamcollsurg.2020.08.761
2 Insights on
- Improved Nonalcoholic Fatty Liver Disease
- High evidence
- Clinical
The secondary endpoints were the incidences of NAFLD at 1, 3, 6, and 12 months and the rate of improvement in NAFLD with high-dose transfer in the control group.
Effect
Neutral
Effect size
Small
Significant
No
Dose
3.0 g/day